Navigation Links
GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vaccine Trial
Date:9/24/2007

p>

GeoVax AIDS vaccines are being prepared to enter Phase 2 human trials. These large trials will expand the safety and positive immune response data demonstrated in the five (5) prior GeoVax AIDS vaccine trial groups. These trials will be conducted in collaboration with the HIV Vaccine Trials Network.

On the basis of non-human primate studies, GeoVax believes its vaccines will be safe and protective. A rigorously conducted clinical trial in human volunteers will be accomplished to confirm effectiveness in preventing AIDS. With 14,000 new HIV/AIDS infections reported daily and more than 60 million people living with HIV/AIDS worldwide, the need for an effective HIV/AIDS vaccine is extremely urgent.

Note: The US Food and Drug Administration (FDA) has established and oversees the regulatory guidelines for clinical trials in the United States and requires regular reports on the progress of clinical trials. The HIV Vaccine Trials Network provides a unifying structure for trials of candidate HIV/AIDS vaccines.

About GeoVax Labs, Inc. (http://www.geovax.com)

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 filed patent applications and issued patents.

GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating individuals prior to their infection with the AIDS virus. GeoVax vaccine regimens employ a "prime-boost" strategy where its DNA vaccine "primes" the immune response and is followed by administration of the GeoVax MVA (Modified Vaccinia Virus) booster vaccination. Both vaccines deliver over 50% of the AIDS virus components but cannot cause AIDS. In addition, GeoVax AIDS vaccines may b
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
3. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
6. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
9. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
10. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
11. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Conn., Sept. 21 In a platform presentation at ... the Study of Diabetes (EASD) in Stockholm, investigators for ... the results of a clinical study evaluating a new ... (Profil Institute for Metabolic Research, Neuss, Germany) and colleagues ...
... Inc. (Nasdaq: VVUS ) today announced positive ... Controlled Release Capsules, an investigational therapy for treatment of ... Americans. The findings come from the ... subset of patients who completed the previously reported 56-week ...
Cached Medicine Technology:Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 2Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 3New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 2New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 3New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 4New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 5New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 6
(Date:4/24/2014)... to receive at least if you,re an adolescent and ... found that 15- and 16-year-olds who find pleasure in pro-social ... less likely to become depressed than those who get a ... themselves. , The researchers detail their findings in the ... study focused on the ventral striatum, a brain region that ...
(Date:4/24/2014)... Science Foundation has awarded LSU Health Sciences Center ... Site grant in the amount of $295,635. The ... diverse social and educational backgrounds, underrepresented in the ... The project will provide students with training for ... It will be led by Principal Investigator Dr. ...
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
(Date:4/23/2014)... O,Shea, M.D., scientific director at the National Institute of ... named the 2014 recipient of the Ross Prize in ... journal Molecular Medicine . The award will be ... of Sciences in Manhattan, followed by scientific presentations by ... of the National Institutes of Health. , The award, ...
(Date:4/23/2014)... Ind. - Purdue University researchers have developed a way ... cell by using tiny gold particles with tails of ... of agricultural and biological engineering, used gold nanoparticles to ... as BRCA1 messenger RNA splice variants, which can indicate ... of these mRNA splice variants in a cell can ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... project to manage the potential shortage of bird flu vaccine ... preparation, would soon be initiated by Chugai Pharmaceutical Company, a ... Health, Labor and Welfare of Japan is said to have ... bird flu vaccine is hoped to being in the next ...
... billion in health reforms. But his off-handed statement has outraged ... there was more mental illness previously which we are not ... on with one’s life. ,This comment was labeled ... he said that in reality mental illness is still considered ...
... bird flu infection in nearly 8 birds, the Hong Kong ... rental system) in possession of animal or bird without prior ... a deduction of five penalty points. ,. ,In ... to pay a fine of 100, 000 HK dollars, according ...
... off at lunch breaks, coughing up ?4,500 for Jiffy breast ... such breast implant operations//, and is getting into the News ... was one of the first to be on their operation ... her mom and a student loan. She said: "You ...
... genetic and environmental factors in the incidence of common ... major research studies// The National Institutes of Health (NIH) ... environment and the disease would form the main focus ... around the significance of genetic variation in increasing or ...
... A new study by Margaret Marshall of Seattle Pacific University ... that the strategy// of expecting the worst results after an ... individuals who adopt such defensive pessimism are not better off ... issue of the journal Cognition and Emotion, the excretes of ...
Cached Medicine News:Health News:NIH To Launch Two Major Gene and Disease Projects Soon 2
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery....
A pocket-sized pulse oximeter. Perfect for the physician's office, emergency medicine, hospitals and clinics, and home health care....
... Cost-effective, portable, continuous, or spot ... with alarms and an internal ... and Sleep Study modes make ... the hospital or clinical environment; ...
... Sleep Hand-Held Pulse Oximeter with built-in ... sleep screening studies in the sleep ... With its easy-to-use, 2-key operation, it ... of SpO 2 , pulse rate ...
Medicine Products: